|
Anti-CD19/CD22 Dual-Target Cord Blood CAR-T Cells Clinical Trials
1 actively recruiting trial
Pipeline
Phase 1: 1
Top Sponsors
- Ruijin Hospital1
Indications
- B-cell Acute Lymphoblastic Leukemia1
- Cancer1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.